News coverage about IRIDEX (NASDAQ:IRIX) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. IRIDEX earned a news impact score of 0.24 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 45.8906312685048 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several research firms have issued reports on IRIX. Zacks Investment Research raised shares of IRIDEX from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. Roth Capital reaffirmed a “buy” rating and set a $13.00 price target on shares of IRIDEX in a research note on Friday, November 3rd.

IRIDEX (NASDAQ IRIX) traded down $0.38 during trading on Friday, hitting $7.57. 19,400 shares of the company’s stock traded hands, compared to its average volume of 15,200. IRIDEX has a one year low of $7.43 and a one year high of $16.37. The firm has a market cap of $92.06, a PE ratio of -4.43 and a beta of 1.31.

IRIDEX (NASDAQ:IRIX) last released its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.27) earnings per share (EPS) for the quarter. IRIDEX had a negative return on equity of 23.21% and a negative net margin of 42.22%. sell-side analysts anticipate that IRIDEX will post -0.87 EPS for the current year.

In related news, CEO William M. Moore bought 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were acquired at an average cost of $7.84 per share, with a total value of $39,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.01% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “IRIDEX (IRIX) Given Daily News Impact Score of 0.24” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://theolympiareport.com/2018/01/19/iridex-irix-given-daily-news-impact-score-of-0-24.html.

About IRIDEX

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).

Insider Buying and Selling by Quarter for IRIDEX (NASDAQ:IRIX)

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.